Wednesday, Jan. 11, 2023 Developing Mucosal Vaccines for Respiratory Viruses Vaccines that provide long-lasting protection against influenza, coronaviruses and respiratory syncytial virus (RSV) have proved exceptionally difficult to develop. NIAID researchers explore the challenges and outline approaches to improved vaccines in a new review article in Cell Host & Microbe. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107